News

Darnell Dent, principal of Dent Advisory Services and a member of the Managed Healthcare Executive® Editorial Advisory Board, discusses health disparities for people of color - specifically Blacks and Latinos - and how COVID-19 has highlighted our failure at the intersection of public health, healthcare and social justice.

Sodium glucose co-transporter 2 (SGLT2) inhibitors have already remade the diabetes drug market. Now competition for new cardiac and renal indications is heating up among three of the main drugs in the class: Janssen’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin), and Eli Lilly/Boehringer-Ingelheim’s Jardiance (empagliflozin).

Some “don’t give a damn about their fellow man.” But in this first of four-part video series, the Johns Hopkins professor, former chief medical and scientific officer of the American Cancer Society, and MHE Editorial Advisory Board member is encouraged by diversity among protestors and the broadening of the efforts to tackle disparities of all kinds. “I think this is a long-term effort.”

The benefits space is changing and there is currently a shift to “enviable benefits” - ones that go beyond traditional health and retirement coverage. Many companies, especially those still doing well during the economic downturn, have ramped up benefits communication about existing support programs such as telemedicine, financial well-being and childcare.

In this week’s episode of Tuning Into the C-Suite, MHE's Briana Contreras spoke with Denise Basow, president and CEO of Clinical Effectiveness at Wolters Kluwer. Briana and Basow discussed the importance of uniting prescribers and pharmacists at the point of care and how this form of care can create more efficient and effective operations within health systems.

Battling racial bias in the workplace. How implementing an inclusion, diversity, equity and accessibility training initiative can lead to better results in racial disparities within healthcare and beyond.